Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model
December 9th, 2018
In this study, we modify an existing experimental method to obtain more reproducible results, by establishing a middle cerebral artery occlusion (MCAO) mouse model. Oral administration of Glycyrrhizae Radix et Rhizome (GR) methanol extract (GRex), following stroke induction, significantly decreased total infarction volume relative to the untreated control group.
Overview
This study modifies an existing experimental method to enhance reproducibility by establishing a middle cerebral artery occlusion (MCAO) mouse model. The oral administration of Glycyrrhizae Radix et Rhizome (GR) methanol extract (GRex) post-stroke induction significantly reduced total infarction volume compared to the untreated control group.
Key Study Components
Area of Science
- Neuroscience
- Traditional medicine
Background
- Stroke models are crucial for studying neuroprotective compounds.
- Glycyrrhizae Radix et Rhizome is known for its medicinal properties.
- Reproducibility in experimental methods is essential for reliable results.
Purpose of Study
- To improve the MCAO model for stroke research.
- To evaluate the neuroprotective effects of GRex.
- To establish a method for screening natural compounds.
Methods Used
- Modification of the MCAO technique for better reproducibility.
- Oral administration of GRex following stroke induction.
- Measurement of total infarction volume in mouse models.
- Visual demonstration of the MCAO procedure.
Main Results
- GRex significantly decreased total infarction volume.
- The modified MCAO method yielded more consistent results.
- Visual demonstration enhanced understanding of the procedure.
Conclusions
- The modified MCAO model is effective for stroke research.
- GRex shows potential as a neuroprotective agent.
- This method can facilitate further research in neuroprotection.
Frequently Asked Questions
Executive Industry Relevance
This study addresses a critical challenge in stroke drug discovery: inconsistent infarct volumes in MCAO models that confound neuroprotective compound screening. By optimizing filament thickness to improve reproducibility, the method enhances predictive confidence in target validation and lead identification pipelines. The demonstrated neuroprotective effect of Glycyrrhizae Radix et Rhizoma extract (GRex) supports its evaluation as a mechanistic de-risking candidate in preclinical stroke therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding natural compound neuroprotection in ischemia-reperfusion injury.
- Operational Value: Provides a biologically de-risked system for functional target validation of stroke pathways.
- Predictive Value: Supports portfolio triage by reducing false positives in early neuroprotective screening.
Screening & Assay Development
- Assay Readiness: Delivers a standardized, reproducible MCAO model with quantified infarct volume as a quantitative endpoint.
- Scalability: Facilitates preparation of validated biological systems for downstream compound evaluation workflows.
- Platform Reuse: Establishes a reliable system for screening additional neuroprotective natural or synthetic compounds.
Translational & Preclinical Research
- Disease Relevance: Uses a clinically relevant transient MCAO mouse model to mimic human stroke pathophysiology.
- Translational Continuity: Connects discovery-stage target validation to preclinical efficacy assessment via histological cell survival metrics.
- Risk-Adjusted Decisions: Enables data-driven go/no-go choices based on infarct volume reduction and cell survival improvements.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, supporting early target validation through reproducible disease modeling and enabling lead identification via quantitative neuroprotection readouts.
- Discovery Biology: Supports hypothesis testing and pathway clarification in ischemic injury models.
- Screening: Delivers assay standardization and reproducibility for reliable compound evaluation.
- Analytics: Provides infarct volume quantification and histological staining outputs for comparative condition analysis.
- Translational Research: Connects to preclinical validation through H&E and cresyl violet staining as biomarkers of neuronal integrity.
- Enterprise Reuse: Frames the MCAO model as a reusable capability for neuroprotective compound screening campaigns.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity in stroke pathways.
- Operational Value: Standardization, reproducibility, and scalability of infarct volume measurements.
- Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk in neuroprotection programs.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on infarct volume and cell survival data.
Implementation Considerations
- Required expertise in neuroscience techniques, microsurgery, and histological staining.
- Instrumentation needs include laser Doppler flow meter, stereomicroscope, cryostat, and imaging systems.
- Cross-team standardization requires consistent filament thickness, occlusion duration, and reperfusion timing.
- Adaptation considerations across rodent strains and sex-specific models.
- Practical limitations include technical variability in filament insertion and reperfusion completeness.
Biopharma FAQs
Chapters in this video
0:04
Title
0:51
Glycyrrhizae Radix et Rhizome (GR) Methanol Extract (GRex) Preparation
2:05
Mouse Middle Cerebral Artery Occlusion (MCAO) Model
4:10
Measurement of Volume of Damaged Brain Tissue
5:02
Hematoxylin and Eosin (H&E) and Cresyl Violet Staining
7:18
Results: Representative GRex Treatment Effects on MCAO-Injured Mice
8:24
Conclusion
